Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xylitol Nasal Spray vs. Placebo for Acute COVID-19 Infection
NCT04610801Phase 3Withdrawn
- Sponsor
- Larkin Community Hospital
- Start
- Dec 2021
- Primary completion
- Jun 2022
- Countries
- 1
01
Overview
Phase 3, randomised trial of Xlear Nasal Spray in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Larkin Community Hospital. Primary endpoint: Change from baseline reactive to non-reactive on COVID 19 RT PCR at 7 days. Planned start Dec 2021; status: withdrawn.
02
Drugs
Xlear Nasal Spray
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04610801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04610801.